Skip to main content

Advertisement

SpringerLink
Log in

Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management

  • Melanoma
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Extracapsular spread (ECS) is recognized to be a high-risk factor in melanoma patients with macrometastatic (N+) nodal disease; however, ECS risk in sentinel lymph node (SLN) biopsy, micrometastatic stage III disease is ambiguous.

Objective

The aim of this study was to examine ECS incidence and its prognostic significance.

Methods

A two-center, retrospective analysis of all patients with micro/macrometastatic lymphadenopathy undergoing nodal surgery from 2008 to 2014 was performed. Patient demographics, tumor characteristics, nodal ECS status, and patient outcomes were collected.

Results

Overall, 515 patients with nodal disease were identified (males/females = 277/238); median age was 63 years (range 17–94). There was an increased frequency of ECS disease in N+ disease compared with SLN+ disease (52.4% vs. 16.2%; p < 0.0001). The absolute disease-specific survival (DSS) difference for SLN+ patients was approximately 30% at 10 years (66.2% vs. 37.2%; p < 0.0001), and the prognosis of SLN+/ECS+ patients was identical to N+/ECS− patients. Multivariate analysis demonstrated that ECS status was an independent prognostic indicator for DSS (hazard ratio 2.47, 95% confidence interval 1.87–3.26; p < 0.0001) in patients with SLN+ disease. There were significant differences in nodal burden according to ECS status between the SLN+ and N+ subgroups suggestive of differing biology in ECS+ tumors.

Conclusion

We found that ECS is a significant DSS, progression-free survival, and overall survival indicator in SLN+ and N+ disease. We demonstrated that ECS upstages stage III disease, similar to ulceration in primary melanoma (stage I/II disease). A simplified staging system substituting ECS for N stage accurately stages patients according to prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105–10.

    Article  Google Scholar 

  2. Clark JR, Shaw D. Extracapsular spread. In: Kountakis SE (ed). Encyclopedia of otolaryngology, head and neck surgery. Berlin: Springer; 2013, pp. 851–852. https://doi.org/10.1007/978-3-642-23499-6_200162.

    Chapter  Google Scholar 

  3. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049–60.

    Article  Google Scholar 

  4. Agrawal S, Kane JM 3rd, Guadagnolo BA, Kraybill WG, Ballo MT. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer. 2009;115(24):5836–44.

    Article  Google Scholar 

  5. Lee RJ, Gibbs JF, Proulx GM, Kollmorgen DR, Jia C, Kraybill WG. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2000;46(2):467–74.

    Article  CAS  Google Scholar 

  6. Dewar DJ, Newell B, Green MA, Topping AP, Powell BWEM, Cook MG. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22(16):3345–9.

    Article  CAS  Google Scholar 

  7. Starz H, Balda BR, Krämer KU, Büchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91(11):2110–21.

    Article  CAS  Google Scholar 

  8. van Akkooi ACJ, de Wilt JHW, Verhoef C, et al. Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol. 2006;17(10):1578–85. https://doi.org/10.1093/annonc/mdl176.

    Article  PubMed  Google Scholar 

  9. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22.

    Article  Google Scholar 

  10. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757–67.

    Article  Google Scholar 

  11. Melanoma: assessment and management. Guidance and guidelines. NICE. https://www.nice.org.uk/guidance/ng14. Accessed 22 Nov 2018.

  12. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367–402.

    Article  CAS  Google Scholar 

  13. U.S. Department of Health and Human Services: Food and Drug Administration. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. FDA.gov. https://www.fda.gov/media/71195/download. Published December 2108. Accessed 13 Jun 2020.

  14. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

    Article  Google Scholar 

  15. Debarbieux S, Duru G, Dalle S, Béatrix O, Balme B, Thomas L. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007;157(1):58–67. https://doi.org/10.1111/j.1365-2133.2007.07937.x.

    Article  CAS  PubMed  Google Scholar 

  16. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201(1):37–47.

    Article  Google Scholar 

  17. Moncrieff MD, Martin R, O’Brien CJ, et al. Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients? Ann Surg Oncol. 2008;15(11):3022–7.

    Article  Google Scholar 

  18. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609.

    Article  CAS  Google Scholar 

  19. Rao UNM, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of eastern cooperative oncology group trial E1690. J Clin Oncol. 2002;20(8):2053–7. https://doi.org/10.1200/jco.2002.08.024.

    Article  CAS  PubMed  Google Scholar 

  20. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124(9):1051–5.

    Article  CAS  Google Scholar 

  21. Coit D. The enigma of regional lymph nodes in melanoma. N Engl J Med. 2017;376(23):2280–1.

    Article  Google Scholar 

  22. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622–34.

    Article  CAS  Google Scholar 

  23. Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–30.e14.

    Article  CAS  Google Scholar 

  24. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–30.

    Article  CAS  Google Scholar 

  25. Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–45.

    Article  CAS  Google Scholar 

Download references

Funding

Ryckie Wade is a Doctoral Research Fellow funded by the National Institute for Health Research (NIHR; DRF-2018-11-ST2-028). The views expressed in this article are those of the authors and not necessarily those of the UK National Health Service, NIHR, or Department of Health.

Author information

Authors and Affiliations

  1. Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospital, Norwich, UK

    Michelle Lo MRCS, Martin Heaton FRCS(Plast) & Marc Moncrieff FRCS(Plast)

  2. Faculty of Medicine and Health, University of Leeds, Leeds, UK

    Alyss Robinson MRes & Ryckie Wade MRCS

  3. Department of Plastic and Reconstructive Surgery, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    Ryckie Wade MRCS, Howard Peach FRCS(Plast) & Donald Dewar FRCS(Plast)

  4. Norwich Medical School, University of East Anglia, Norwich, UK

    Marc Moncrieff FRCS(Plast)

Authors
  1. Michelle Lo MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alyss Robinson MRes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryckie Wade MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Howard Peach FRCS(Plast)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald Dewar FRCS(Plast)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Heaton FRCS(Plast)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc Moncrieff FRCS(Plast)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michelle Lo MRCS.

Ethics declarations

Disclosure

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lo, M., Robinson, A., Wade, R. et al. Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management. Ann Surg Oncol 28, 1642–1653 (2021). https://doi.org/10.1245/s10434-020-09099-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-09099-w

Search

Navigation